Market Research Logo

Commercial Interests at ASGCT 2017 - A 1stOncology Insights Report

1 Executive Summary
2 About 1stOncology™ Insights
2.1 Scope and Methodology
3 Table of Contents
3.1 List of Figures
3.2 List of Tables
4 Major Recent Developments on Cancer Drugs at ASGCT from 2016 to Present
4.1 Positive Highlights on ASGCT Cancer Drugs
4.2 Negative Highlights on ASGCT Cancer Drugs
5 Overview of Cancer Drugs at ASGCT 2017
5.1 Pipeline Breakdown and Status
5.2 From Small Molecules to Biologics
5.3 Analysis of the Drug Target Landscape
5.4 Pursued Tumor Types
5.5 Biomarkers and Combination Therapies Review
5.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
5.7 Drug Innovators
6 ASGCT 2017 by Startups
6.1 Pipeline Breakdown and Status
6.2 Compound Review
6.3 Target Analysis
6.4 Pursued Tumor Types
6.5 Biomarkers and Combination Therapies Review
6.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
6.7 Drug Innovators
7 ASGCT 2017 by Fierce 15 Companies
7.1 Pipeline Breakdown and Status
7.2 Compound Review
7.3 Target Analysis
7.4 Pursued Tumor Types
7.5 Biomarkers and Combination Therapies Review
7.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
7.7 Drug Innovators
8 ASGCT 2017 by Orphan Drugs
8.1 Pipeline Breakdown and Status
8.2 Compound Review
8.3 Target Analysis
8.4 Pursued Tumor Types
8.5 Biomarkers and Combination Therapies Review
8.6 Breakthrough Drugs and Sales Data Figures
8.7 Drug Innovators
9 ASGCT 2017 by Breakthrough Therapies
9.1 Pipeline Breakdown and Status
9.2 Compound Review
9.3 Target Analysis
9.4 Pursued Tumor Types
9.5 Biomarkers and Combination Therapies Review
9.6 Orphan Drugs and Sales Data Figures
9.7 Drug Innovators
10 ASGCT 2017 by Cancer Vaccines
10.1 Pipeline Breakdown and Status
10.2 Compound Review
10.3 Target Analysis
10.4 Pursued Tumor Types
10.5 Biomarkers and Combination Therapies Review
10.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
10.7 Drug Innovators
11 ASGCT 2017 by CAR/TCR Therapies
11.1 Pipeline Breakdown and Status
11.2 Compound Review
11.3 Target Analysis
11.4 Pursued Tumor Types
11.5 Biomarkers and Combination Therapies Review
11.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
11.7 Drug Innovators
12 ASGCT 2017 by Immune Checkpoint Drugs
12.1 Pipeline Breakdown and Status
12.2 Compound Review
12.3 Target Analysis
12.4 Pursued Tumor Types
12.5 Biomarkers and Combination Therapies Review
12.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
12.7 Drug Innovators
13 ASGCT 2017 by Oncolytic Viruses
13.1 Pipeline Breakdown and Status
13.2 Compound Review
13.3 Target Analysis
13.4 Pursued Tumor Types
13.5 Biomarkers and Combination Therapies Review
13.6 Orphan Drugs, Breakthrough Drugs and Sales Data Figures
13.7 Drug Innovators
14 Disclaimer
15 Drug Index
16 Drug Innovator Index
1.1 List of Figures
Figure 1: Pipeline Breakdown and Status of Cancer Drugs at ASGCT 2017
Figure 2: Compound Review of Cancer Drugs at ASGCT 2017
Figure 3: Target Analysis of Cancer Drugs at ASGCT 2017
Figure 4: Pursued Tumor Types of Cancer Drugs at ASGCT 2017
Figure 5: Biomarker Development and Combination Therapies among Cancer Drugs at ASGCT 2017
Figure 6: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Drugs at ASGCT 2017
Figure 7: Drug Innovators Behind Cancer Drugs at ASGCT 2017
Figure 8: Pipeline Breakdown and Status of Startup Affiliated Drugs at ASGCT 2017
Figure 9: Compound Review of Startup Affiliated Drugs at ASGCT 2017
Figure 10: Target Analysis of Startup Affiliated Drugs at ASGCT 2017
Figure 11: Pursued Tumor Types of Startup Affiliated Drugs at ASGCT 2017
Figure 12: Biomarker Development and Combination Therapies among Startup Affiliated Drugs at ASGCT 2017
Figure 13: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Startup Affiliated Drugs at ASGCT 2017
Figure 14: Drug Innovators Behind Startup Affiliated Drugs at ASGCT 2017
Figure 15: Pipeline Breakdown and Status of Fierce 15 Affiliated Drugs at ASGCT 2017
Figure 16: Compound Review of Fierce 15 Affiliated Drugs at ASGCT 2017
Figure 17: Target Analysis of Fierce 15 Affiliated Drugs at ASGCT 2017
Figure 18: Pursued Tumor Types of Fierce 15 Affiliated Drugs at ASGCT 2017
Figure 19: Biomarker Development and Combination Therapies among Fierce 15 Affiliated Drugs at ASGCT 2017
Figure 20: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Fierce 15 Affiliated Drugs at ASGCT 2017
Figure 21: Drug Innovators Behind Fierce 15 Affiliated Drugs at ASGCT 2017
Figure 22: Pipeline Breakdown and Status of Orphan Drugs at ASGCT 2017
Figure 23: Compound Review of Orphan Drugs at ASGCT 2017
Figure 24: Target Analysis of Orphan Drugs at ASGCT 2017
Figure 25: Pursued Tumor Types of Orphan Drugs at ASGCT 2017
Figure 26: Biomarker Development and Combination Therapies among Orphan Drugs at ASGCT 2017
Figure 27 Breakthrough Drugs and Sales Data Figures Among Orphan Drugs at ASGCT 2017
Figure 28: Drug Innovators Behind Orphan Drugs at ASGCT 2017
Figure 29: Pipeline Breakdown and Status of Breakthrough Therapy Drugs at ASGCT 2017
Figure 30: Compound Review of Breakthrough Therapy Drugs at ASGCT 2017
Figure 31: Target Analysis of Breakthrough Therapy Drugs at ASGCT 2017
Figure 32: Pursued Tumor Types of Breakthrough Therapy Drugs at ASGCT 2017
Figure 33: Biomarker Development and Combination Therapies among Breakthrough Therapy Drugs at ASGCT 2017
Figure 34: Orphan Drugs and Sales Data Figures Among Breakthrough Therapy Drugs at ASGCT 2017
Figure 35: Drug Innovators Behind Breakthrough Therapy Drugs at ASGCT 2017
Figure 36: Pipeline Breakdown and Status of Cancer Vaccines at ASGCT 2017
Figure 37: Compound Review of Cancer Vaccines at ASGCT 2017
Figure 38: Target Analysis of Cancer Vaccines at ASGCT 2017
Figure 39: Pursued Tumor Types of Cancer Vaccines at ASGCT 2017
Figure 40: Biomarker Development and Combination Therapies among Cancer Vaccines at ASGCT 2017
Figure 41: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Cancer Vaccines at ASGCT 2017
Figure 42: Drug Innovators Behind Cancer Vaccines at ASGCT 2017
Figure 43: Pipeline Breakdown and Status of CAR/TCR Therapies at ASGCT 2017
Figure 44: Compound Review of CAR/TCR Therapies at ASGCT 2017
Figure 45: Target Analysis of CAR/TCR Therapies at ASGCT 2017
Figure 46: Pursued Tumor Types of CAR/TCR Therapies at ASGCT 2017
Figure 47: Biomarker Development and Combination Therapies among CAR/TCR Therapies at ASGCT 2017
Figure 48: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among CAR/TCR Therapies at ASGCT 2017
Figure 49: Drug Innovators Behind CAR/TCR Therapies at ASGCT 2017
Figure 50: Pipeline Breakdown and Status of Immune Checkpoint Drugs at ASGCT 2017
Figure 51: Compound Review of Immune Checkpoint Drugs at ASGCT 2017
Figure 52: Target Analysis of Immune Checkpoint Drugs at ASGCT 2017
Figure 53: Pursued Tumor Types of Immune Checkpoint Drugs at ASGCT 2017
Figure 54: Biomarker Development and Combination Therapies among Immune Checkpoint Drugs at ASGCT 2017
Figure 55: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Immune Checkpoint Drugs at ASGCT 2017
Figure 56: Drug Innovators Behind Immune Checkpoint Drugs at ASGCT 2017
Figure 64: Pipeline Breakdown and Status of Oncolytic Viruses Drugs at ASGCT 2017
Figure 65: Compound Review of Oncolytic Viruses Drugs at ASGCT 2017
Figure 66: Target Analysis of Oncolytic Viruses Drugs at ASGCT 2017
Figure 67: Pursued Tumor Types of Oncolytic Viruses Drugs at ASGCT 2017
Figure 68: Biomarker Development and Combination Therapies among Oncolytic Viruses Drugs at ASGCT 2017
Figure 69: Orphan Drugs, Breakthrough Drugs and Sales Data Figures Among Oncolytic Viruses Drugs at ASGCT 2017
Figure 70: Drug Innovators Behind Oncolytic Viruses Drugs at ASGCT 2017
1.2 List of Tables
Table 1: Pipeline Table by Stage of Cancer Drugs at ASGCT 2017
Table 2: Pipeline Table by Compound Type of Cancer Drugs at ASGCT 2017
Table 3: Pipeline Table by Target of Cancer Drugs at ASGCT 2017
Table 5: Pipeline Table by Tumor Type of Cancer Drugs at ASGCT 2017
Table 6: Pipeline Table of Drugs with Biomarker Development and in Combination Therapies among Cancer Drugs at ASGCT 2017
Table 7: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Cancer Drugs at ASGCT 2017
Table 8: Pipeline Table by Drug Innovators Behind Cancer Drugs at ASGCT 2017
Table 9: Pipeline Table by Highest Development Stage of Startup Affiliated Drugs at ASGCT 2017
Table 10: Pipeline Table by Compound Type of Startup Affiliated Drugs at ASGCT 2017
Table 11: Pipeline Table by Target of Startup Affiliated Drugs at ASGCT 2017
Table 12: Pipeline Table by Tumor Type of Startup Affiliated Drugs at ASGCT 2017
Table 13: Pipeline Table of Startup Affiliated Drugs at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 14: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Startup Affiliated Drugs at ASGCT 2017
Table 15: Pipeline Table by Drug Innovators of Startup Affiliated Drugs at ASGCT 2017
Table 16: List of Identified Startup Companies Linked To Drugs at ASGCT 2017
Table 17: Pipeline Table by Highest Development Stage of Fierce 15 Affiliated Drugs at ASGCT 2017
Table 18: Pipeline Table by Compound Type of Fierce 15 Affiliated Drugs at ASGCT 2017
Table 19: Pipeline Table by Target of Fierce 15 Affiliated Drugs at ASGCT 2017
Table 20: Pipeline Table by Tumor Type of Fierce 15 Affiliated Drugs at ASGCT 2017
Table 21: Pipeline Table of Fierce 15 Affiliated Drugs at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 22: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Fierce 15 Affiliated Drugs at ASGCT 2017
Table 23: Pipeline Table by Drug Innovators of Fierce 15 Affiliated Drugs at ASGCT 2017
Table 24: List of Identified Fierce 15 Companies Linked To Drugs at ASGCT 2017
Table 25: Pipeline Table by Highest Development Stage of Orphan Drugs at ASGCT 2017
Table 26: Pipeline Table by Compound Type of Orphan Drugs at ASGCT 2017
Table 27: Pipeline Table by Target of Orphan Drugs at ASGCT 2017
Table 28: Pipeline Table by Tumor Type of Orphan Drugs at ASGCT 2017
Table 29: Pipeline Table of Orphan Drugs at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 30: Pipeline Table of Breakthrough Drugs and Drugs with Sales Data Figures Orphan Drugs at ASGCT 2017
Table 31: Pipeline Table by Drug Innovators of Orphan Drugs at ASGCT 2017
Table 32: Pipeline Table by Highest Developmental Stage of Breakthrough Therapy Drugs at ASGCT 2017
Table 33: Pipeline Table by Compound Type of Breakthrough Therapy Drugs at ASGCT 2017
Table 34: Pipeline Table by Target of Breakthrough Therapy Drugs at ASGCT 2017
Table 35: Pipeline Table by Tumor Type of Breakthrough Therapy Drugs at ASGCT 2017
Table 36: Pipeline Table of Breakthrough Therapy Drugs at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 37: Pipeline Table of Orphan Drugs and Drugs with Sales Data Figures Among Breakthrough Therapy Drugs at ASGCT 2017
Table 38: Pipeline Table by Drug Innovators of Breakthrough Therapy Drugs at ASGCT 2017
Table 39: Pipeline Table by Highest Development Stage of Cancer Vaccines at ASGCT 2017
Table 40: Pipeline Table by Compound Type of Cancer Vaccines at ASGCT 2017
Table 41: Pipeline Table by Target of Cancer Vaccines at ASGCT 2017
Table 42: Pipeline Table by Tumor Type of Cancer Vaccines at ASGCT 2017
Table 43: Pipeline Table of Cancer Vaccines at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 44: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Cancer Vaccines at ASGCT 2017
Table 45: Pipeline Table by Drug Innovators of Cancer Vaccines at ASGCT 2017
Table 46: Pipeline Table by Highest Development Stage of CAR/TCR Therapies at ASGCT 2017
Table 47: Pipeline Table by Compound Type of CAR/TCR Therapies at ASGCT 2017
Table 48: Pipeline Table by Target of CAR/TCR Therapies at ASGCT 2017
Table 49: Pipeline Table by Tumor Type of CAR/TCR Therapies at ASGCT 2017
Table 50: Pipeline Table of CAR/TCR Therapies at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 51: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among CAR/TCR Therapies at ASGCT 2017
Table 52: Pipeline Table by Drug Innovators of CAR/TCR Therapies at ASGCT 2017
Table 53: Pipeline Table by Stage of Immune Checkpoint Drugs at ASGCT 2017
Table 54: Pipeline Table by Compound Type of Immune Checkpoint Drugs at ASGCT 2017
Table 55: Pipeline Table by Target of Immune Checkpoint Drugs at ASGCT 2017
Table 56: Pipeline Table by Tumor Type of Immune Checkpoint Drugs at ASGCT 2017
Table 57: Pipeline Table of Immune Checkpoint Drugs at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 58: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Immune Checkpoint Drugs at ASGCT 2017
Table 59: Pipeline Table by Drug Innovators of Immune Checkpoint Drugs at ASGCT 2017
Table 67: Pipeline Table by Highest Development Stage of Oncolytic Viruses Drugs at ASGCT 2017
Table 68: Pipeline Table by Compound Type of Oncolytic Viruses Drugs at ASGCT 2017
Table 69: Pipeline Table by Target of Oncolytic Viruses Drugs at ASGCT 2017
Table 70: Pipeline Table by Tumor Type of Oncolytic Viruses Drugs at ASGCT 2017
Table 71: Pipeline Table of Oncolytic Viruses Drugs at ASGCT 2017 with Biomarker Development or In Combination Therapies
Table 72: Pipeline Table of Orphan Drugs, Breakthrough Drugs and Drugs with Sales Data Figures Among Oncolytic Viruses Drugs at ASGCT 2017
Table 73: Pipeline Table by Drug Innovators of Oncolytic Viruses Drugs at ASGCT 2017

Commercial Interests at ASGCT 2017 - A 1stOncology Insights Report

The Commercial Interests at ASGCT 2017 report is a must have companion tool for reviewing the direction of commercial drug development emerging from the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2017. Break through the mountain of almost one thousand abstracts presented at ASGCT 2017 with a focused entry to reveal the identity and position of more than 33 commercial drugs at the core of the oncology landscape.

These identified drugs range from very early development to marketed and in this report are analyzed across eight “hot” areas in oncology, including sections such as exciting Startups, CAR/TCR Therapies, Oncolytic Viruses, Cancer Vaccines and more. Each “hot” area analyzed reveals the core R&D focus of commercial actors, the targeting landscape (with many cases of unique targets not currently under development by any other company), drugs with biomarkers, drugs in combination therapy development and much more.

To further illuminate the reader, this report also includes almost a hundred of the latest references detailing both positive and negative pipeline development among them from throughout 2016 to present. This provides comprehensive insight to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more.

The ASGCT Annual Meeting is a key event on cell and gene therapy which will tell us the direction this fascinating field of therapies is heading in oncology. Consequently, this report is a must read for anyone with an interest in oncology who wants to save time and effort and more successfully analyze the direction emerging from this meeting.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;